References
- VincentFBMorandEFMurphyKMackayFMarietteXMarcelliCAntidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspectiveAnn Rheum Dis20137216517823178294
- CheifetzASmedleyMMartinSThe incidence and management of infusion reactions to infliximab: a large center experienceAm J Gastroenterol2003981315132412818276
- DoreRKMathewsSSchechtmanJThe immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritisClin Exp Rheumatol200725404617417989
- PichlerWJCampiPAdverse side effects to biological agentsPichlerWJDrug HypersensitivityBaselKarger2007160174
- ParishWEShort term anaphylactic IgG antibodies in human seraLancet1970192 (7673):591–592.
- van SchouwenburgPAKrieckaertCLNurmohamedMIgG4 production against adalimumab during long term treatment of RA patientsJ Clin Immunol2012321000100622622790
- AalberseRCvan der GaagRvan LeeuwenLJSerologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted responseJ Immunol19831307227266600252
- TaoMHCanfieldSMMorrisonSLThe differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domainJ Exp Med1991173102510282007852
- NirulaAGlaserSMKalledSLTaylorFRWhat is IgG4? A review of the biology of a unique immunoglobulin subtypeCurr Opin Rheumatol20112311912421124094
- Van Der ZeeJSVan SwietenPAalberseRCSerologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalencyJ Immunol1986137356635713782791
- van der NeutKMSchuurmanJLosenMAnti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchangeScience20073171554155717872445
- van der GiessenMHomanWLvan KernbeekGAalberseRCDiegesPHSubclass typing of IgG antibodies formed by grass pollen-allergic patients during immunotherapyInt Arch Allergy Appl Immunol197650625640773842
- GehlharKSchlaakMBeckerWBufeAMonitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcomeClin Exp Allergy19992949750610202364
- Nouri-AriaKTWachholzPAFrancisJNGrass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocks IgG activityJ Immunol20041723252325914978133
- DeisenhammerFReindlMBergerTImmunoglobulin subclasses in patients with neutralizing and non-neutralizing antibodies against IFN-β1bJ Interferon Cytokine Res20012116717111331039
- SvensonMGeborekPSaxneTBendtzenKMonitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodiesRheumatology (Oxford)2007461828183418032541
- WoutersDStapelSVisMHuman antichimeric antibodies to infliximab and infusion-related allergic reactions in patients with rheumatoid arthritisAllergy Clin Immunol Int20072198200
- AalberseRCStapelSOSchuurmanJRispensTImmunoglobulin G4: an odd antibodyClin Exp Allergy20093946947719222496
- van KuijkAWde GrootMStapelSODijkmansBAWolbinkGJTakPPRelationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritisAnn Rheum Dis20106962462520223840
- BarteldsGMWijbrandtsCANurmohamedMTClinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnn Rheum Dis20076692192617301106
- BarteldsGMKrieckaertCLNurmohamedMTDevelopment of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-upJAMA20113051460146821486979